节点文献

瘤内注射E1B缺失腺病毒(H101)与化疗联合治疗恶性肿瘤的Ⅱ期临床试验

Phase ⅡClinical Study of Intratumoral H101, an E1B Deleted Adenovirus,in Comb ination with Chemotherapy in Patients with Cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 徐瑞华袁中玉管忠震曹烨王华庆胡晓桦冯继峰张阳李方陈正堂王杰军黄建瑾周清华宋三泰

【Author】 Xu Rui-Hua1, Yuan Zhong-Yu1, Guan Zhong-Zhen1, Cao Ye1, Wang Hua-Qing2, Hu Xiao-Hua3, Feng Ji-Feng4, Zhang Yang5, Li Fang6, Chen Zheng-Tang7, Wang Jie-Jun8, Huang Jian-Jin9, Zhou Qing-Hua10, Song San-Tai11 1.Department of Medicine,Cancer Center, Sun Yat-sen University,Guangzhou, Guangdong,510060,P.R.China 2.Department of Medicine,Tumor Hospital,Tianjin Medical University, Tianjin,300060,P.R.China 3.Tumor Hospital,Guangxi Medical University,Nanning,Guangxi,530021, P.R.China 4.Department of Medicine,Jiangsu Province Tumor Hospital,Nanjing, Jiangsu,210009,P.R.China 5.Department of Medicine,Dalian Medical University Affiliated Second Hospital,Dalian,Liaoning,116023, P.R.China 6.Department of Medicine,General Hospital of PLA,Beijing,100853, P.R.China 7.Department of Medicine,Xinqiao Hospital of the Third Medical Military, Chongqing,400037,P.R.China 8.Department of Medicine,Changzheng Hospital of the Second Medical Military, Shanghai,630012,P.R.China 9.Department of Medicine,Zhejiang Medical University Affiliated Second Hospital,Hangzhou,Zhejiang,310017, P.R.China 10.Department of Medicine,Huaxi Medical University Affiliated Hospital, Chengdu,Sichuan,610041,P.R.China 11.Department of Medicine,Cancer Center,Beijing 307 Hospital,Beijing, 100039,P.R.China

【机构】 中山大学肿瘤防治中心天津医科大学附属肿瘤医院广西医科大学附属肿瘤医院江苏省肿瘤医院大连医科大学附属第二医院解放军总医院第三军医大学附属新桥医院第二军医大学附属长征医院浙江医科大学附属第二医院华西医科大学附属第一医院军事医学科学院附属医院 广东广州510060广东广州510060天津300060广西南宁510021江苏南京210009辽宁大连116011北京100853重庆400037上海630012浙江杭州310017四川成都610041北京100039

【摘要】 背景及目的:具有瘤内复制能力的病毒(或称溶瘤病毒)用于治疗恶性肿瘤的研究近年来发展相当迅速,其中E1B缺失腺病毒是目前研究进展最快的溶瘤病毒之一。本研究采用自身对照的方法,观察在全身化疗的同时,部分瘤内注射E1B缺失腺病毒(H101)的近期疗效和不良反应。方法:采用多中心开放式研究。共入选50例,在全身化疗的同时,对目标病灶给予H101瘤内注射,每天1次,每次1支(0.5ml,含5×1011病毒颗粒),连续5天为1疗程。治疗期间同时联合常规化疗。记录疗效并与未注射H101的自身瘤灶对比,同时观察不良反应。结果:在可评价疗效的46例患者中,注射病灶的总有效率为30.4%,而按ITT人群分析有效率为28.0%(14/50),其中CR为3例,PR为11例;对照病灶的总有效率为13.0%,其中CR为1例,PR为5例。注射病灶的有效率明显高于对照病灶(P<0.001)。主要不良反应为注射部位局部疼痛(26.9%)和发热(30.2%),有4例出现Ⅰ级肝功能异常,1例出现Ⅱ级肝功能异常,1例出现Ⅳ级肝功能异常,4例出现Ⅳ级血液学毒性。结论:在全身化疗的同时,瘤内注射E1B缺失腺病毒(H101)对多种不同类型的恶性肿瘤具有一定疗效,其毒副作用较低,易为患者接受。

【Abstract】 BACKGROUND &OBJECTIVE:In recent years,great development have be en made in cancer therapeutics with replication-competent viruses (oncolytic viru ses), E1B deleted adenovirus is one of promising viruses. The current study was designed to evaluate the efficacy and toxicity of intratumoral H101, a E1B-dele ted adenovirus, in combination with chemotherapy on patients with cancer. METHOD S:A total of 50 patients with malignant tumors in multiple centers clinical tria l were treated with H101, 0.5ml 5×1011 viral particle per day for 5 consecutive days every three weeks. Routine chemotherapy was performed at the same time. An d the efficacy and toxicity were recorded. RESULTS:Among 46 valuable cases, the overall response rate was 30.4%. The response rate was 28.0%(14/50) among ITT population, including 3 complete response (CR) and 11 partial response (PR). The overall response rate of control lesion was 13.0%,including 1 case of CR and 5 cases of PR. Thus,the response rate in injected lesion is clearly higher than t hat in control lesion (P< 0 001). Main side effects were injection site pain (2 6.9%) and fever (30.2%). Grade 1 hepatic dysfunction was found in 4 patients, grade 2 in 1 patients, grade 4 in 1 patients. Grade 4 hematological toxicities w ere found in 4 patients. CONCLUSION:The study showed that the combination of gen etically modified adenovirus (H101) and chemotherapy possessed some effect for t reating the patients with refractory malignant tumors, and the toxicities were l ower, well tolerated.

【基金】 国家“863”高科技项目(No.2002AA2Z3304)
  • 【文献出处】 癌症 ,Chinese Journal of Cancer , 编辑部邮箱 ,2003年12期
  • 【分类号】R730.5
  • 【被引频次】32
  • 【下载频次】286
节点文献中: 

本文链接的文献网络图示:

本文的引文网络